Pharmacists in Fort Bragg, North Carolina
74 Pharmacists found in Fort Bragg
Michael Francis Cabaj, PHARMD
Pharmacist - Clinician (PhC)/ Clinical Pharmacy Specialist
2817 Reilly Road, Fort Bragg, NC 28310
910-630-1584
Dr. Michelle Simpson Laurich, PHARMD
Pharmacist
2817 Reilly St Stop A, Inpatient Pharmacy, Fort Bragg, NC 28310
910-585-0226
Dr. Olaide Akintunde, PHARMD
Pharmacist
5-4257 Bastonge Street, Fort Bragg, NC 28310
910-907-2575 910-907-9606
Pamela Taylor Mattocks, RPH
Pharmacist
2655 Reilly St Bldg 4-1571, Fort Bragg, NC 28310
910-908-8392 910-432-9527
Mr. Paul Mcintyre White, RPH
Pharmacist
2817 Reilly St, Outpatient Pharmacy, Fort Bragg, NC 28310
910-907-9262
Dr. Robert Keith Mokszycki, PHARM.D.
Pharmacist - Clinician (PhC)/ Clinical Pharmacy Specialist
2817 Reilly St, Fort Bragg, NC 28310
910-907-8748
Dr. Ronnie Scott Holuby, PHARM.D.
Pharmacist - Pharmacotherapy
2817 Reilly Rd, Womack Army Medical Center, Fort Bragg, NC 28310
910-907-8922 910-907-6069
Dr. Sarah M Voytko, PHARM.D
Pharmacist - Clinician (PhC)/ Clinical Pharmacy Specialist
2817 Reilly St, Fort Bragg, NC 28310
910-907-8680 910-907-8443
Dr. Shaleah Nicole Copeland, PHARMD
Pharmacist
1722 Gruber Rd, Fort Bragg, NC 28310
910-907-9113 910-907-9485
Dr. Shalonda Lichelle Renois, PHARM.D.
Pharmacist
2817 Reilly St, Warrior Transition Unit, Fort Bragg, NC 28310
910-643-1749
Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.